The European Journal of Cancer (including EJC Supplements), is an international comprehensive oncology journal that publishes original research, editorial comments, review articles and news on experimental oncology, clinical oncology (medical, paediatric, radiation, surgical), translational oncology, and on cancer epidemiology and prevention. The Journal now has online submission for authors.
《欧洲癌症杂志》（包括EJC增刊）是一份国际综合性肿瘤学杂志，发表实验肿瘤学、临床肿瘤学（医学、儿科、放射、外科）、转化肿瘤学以及癌症流行病学和预防方面的原创研究、编辑评论、综述文章和新闻。《华尔街日报》现在有作者在线投稿。
Superior skin cancer classification by the combination of human and artificial intelligence.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.019
The impact of chemotherapy on survival of patients with extremity and trunk wall soft tissue sarcoma: revisiting the results of the EORTC-STBSG 62931 randomised trial.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.009
NAPOLI-1 phase 3 study of liposomal irinotecan in metastatic pancreatic cancer: Final overall survival analysis and characteristics of long-term survivors.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.007
Human leukocyte antigen variation is associated with adverse events of checkpoint inhibitors.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.009
Performance of the Food and Drug Administration/EMA-approved programmed cell death ligand-1 assays in urothelial carcinoma with emphasis on therapy stratification for first-line use of atezolizumab and pembrolizumab.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.007
Correlation between nivolumab exposure and treatment outcomes in non-small-cell lung cancer.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.008
Randomised phase 2 study of pembrolizumab plus CC-486 versus pembrolizumab plus placebo in patients with previously treated advanced non-small cell lung cancer.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.028
Programmed cell death 1 (PD-1) targeting in patients with advanced osteosarcomas: results from the PEMBROSARC study.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.018
Switch to anti-programmed cell death protein 1 (anti-PD-1) fixed-dose regimen: What is the economic impact?
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.02.016
First-in-human phase I study of the bromodomain and extraterminal motif inhibitor BAY 1238097: emerging pharmacokinetic/pharmacodynamic relationship and early termination due to unexpected toxicity.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.020
Haematological immune-related adverse events with immune checkpoint inhibitors, how to manage?
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.014
Brainstem biopsy in pediatric diffuse intrinsic pontine glioma in the era of precision medicine: the INFORM study experience.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.03.019
A multicentre retrospective cohort study of ovarian germ cell tumours: Evidence for chemotherapy de-escalation and alignment of paediatric and adult practice
来源期刊：European Journal of CancerDOI：10.1016/j.ejca.2019.03.001
Current state of quality of life and patient-reported outcomes research.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.016
Therapeutic relevance of targeted sequencing in management of patients with advanced biliary tract cancer: DNA damage repair gene mutations as a predictive biomarker.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.022
ACCELERATE and European Medicine Agency Paediatric Strategy Forum for medicinal product development for mature B-cell malignancies in children.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.01.013
Delayed immune-related adverse events in assessment for dose-limiting toxicity in early phase immunotherapy trials.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.017
Dynamic risk assessment based on positron emission tomography scanning in diffuse large B-cell lymphoma: Post-hoc analysis from the PETAL trial.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.09.027
Evolution and recurrence of gastrointestinal immune-related adverse events induced by immune checkpoint inhibitors.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.006
Association of clinical outcomes in metastatic breast cancer patients with circulating tumour cell and circulating cell-free DNA.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.012
Real-world efficacy and safety of lenvatinib: data from a compassionate use in the treatment of radioactive iodine-refractory differentiated thyroid cancer patients in Italy.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.05.031
Three-year follow-up from a phase 3 study of SB3 (a trastuzumab biosimilar) versus reference trastuzumab in the neoadjuvant setting for human epidermal growth factor receptor 2-positive breast cancer.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.015
Establishing the European Norm for the health-related quality of life domains of the computer-adaptive test EORTC CAT Core.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.023
Circulating innate immune markers and outcomes in treatment-naïve advanced non-small cell lung cancer patients.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.017
State of clinical research of radiotherapy/chemoradiotherapy and immune checkpoint inhibitor therapy combinations in solid tumours-a German radiation oncology survey.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.026
Contrast enhancement is a prognostic factor in IDH1/2 mutant, but not in wild-type WHO grade II/III glioma as confirmed by machine learning.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.019
Long-term health and social function in adult survivors of paediatric astrocytoma: A report from the Childhood Cancer Survivor Study.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.016
EGFR-TKIs plus bevacizumab demonstrated survival benefit than EGFR-TKIs alone in patients with EGFR-mutant NSCLC and multiple brain metastases.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.021
Chromosome 3q arm gain linked to immunotherapy response in advanced cutaneous squamous cell carcinoma.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.03.004
Perinatal complications in female survivors of cancer: a systematic review and meta-analysis.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.01.104
Challenging the recalcitrant disease-developing molecularly driven treatments for small cell lung cancer.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.04.037
A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.014
A snapshot of current genetic testing practice in Lynch syndrome: The results of a representative survey of 33 Latin American existing centres/registries.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.017
Dynamic clonal remodelling in breast cancer metastases is associated with subtype conversion.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.07.003
The gap in postoperative outcome between older and younger patients with stage I-III colorectal cancer has been bridged; results from the Netherlands cancer registry.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.04.036
Machine learning defined diagnostic criteria for differentiating pituitary metastasis from autoimmune hypophysitis in patients undergoing immune checkpoint blockade therapy.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.06.020
Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.09.024
Impact of anti-thymocyte globulin on results of allogeneic peripheral blood stem cell transplantation for patients with Philadelphia-positive acute lymphoblastic leukaemia: An analysis by the Acute Leukemia Working Party of the EBMT.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.11.003
Vinflunine/gemcitabine versus carboplatin/gemcitabine as first-line treatment in cisplatin-ineligible patients with advanced urothelial carcinoma: A randomised phase II trial (VINGEM).
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.033
5-Hydroxytryptamine1a receptors on tumour cells induce immune evasion in lung adenocarcinoma patients with depression via autophagy/pSTAT3.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.03.017
Cetuximab, fluorouracil and cisplatin with or without docetaxel for patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck (CeFCiD): an open-label phase II randomised trial (AIO/IAG-KHT trial 1108).
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.018
Pooled Analysis of external-beam RADiotherapy parameters in phase II and phase III trials in radiochemotherapy in Anal Cancer (PARADAC).
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.022
Patritumab or placebo, with cetuximab plus platinum therapy in recurrent or metastatic squamous cell carcinoma of the head and neck: A randomised phase II study.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.08.017
Effects of adjuvant tamoxifen over three decades on breast cancer-free and distant recurrence-free interval among premenopausal women with oestrogen receptor-positive breast cancer randomised in the Swedish SBII:2pre trial.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.12.034
Low-molecular-weight heparin adherence and effects on survival within a randomised phase III lung cancer trial (RASTEN).
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.06.015
Avoidable cancers in the Nordic countries-the potential impact of increased physical activity on postmenopausal breast, colon and endometrial cancer.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.01.008
Common genetic variants contribute to incomplete penetrance: evidence from cancer-free BRCA1 mutation carriers.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2018.10.022
Efficacy of molecularly targeted agents given in the randomised trial SHIVA01 according to the ESMO Scale for Clinical Actionability of molecular Targets.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.09.001
Impact of cisplatin dose and smoking pack-years in human papillomavirus-positive oropharyngeal squamous cell carcinoma treated with chemoradiotherapy.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.06.019
Effectiveness of intensive clinical and radiological follow-up in patients with surgically resected NSCLC. Analysis of 2661 patients from the prospective MAGRIT trial.
来源期刊：European journal of cancerDOI：10.1016/j.ejca.2019.11.005
